Australia · Delayed Price · Currency is AUD Chrysos Corporation Earnings Call Transcripts
Fiscal Year 2026
-
Record first half FY 2026 results with 49% revenue and 152% EBITDA growth, driven by global PhotonAssay adoption, high utilization, and expanding deployments. Guidance is reaffirmed at the upper end, with strong funding and accelerating momentum for further growth.
Fiscal Year 2025
-
Revenue and EBITDA grew 46% and 80% year-over-year, driven by strong PhotonAssay adoption and expansion into South America. FY 2026 guidance projects continued growth, with all major labs now partnered and a robust cash position supporting further deployments.
-
Revenue and EBITDA grew 46% and 80% year-over-year, with margin improvement and strong cash reserves. FY2026 guidance projects continued growth, supported by global expansion, new partnerships, and next-gen technology deployment.
-
Revenue rose 54% year-on-year to AUD 29.1 million, with EBITDA up 150% and margin improving to 20%. Six new contracts and five unit deployments support future growth, though revenue is tracking toward the lower end of guidance due to deployment timing.
-
Revenue grew 53% year-over-year to AUD 15.3 million, with record sample volumes for the 24th consecutive quarter and strong international expansion, especially in the Americas. FY 2025 guidance is reaffirmed, and the company remains well-funded for growth, with improved operational efficiency and deepening partnerships with major labs.
-
Revenue rose 54% year-over-year, driven by strong international growth and record sample volumes. Four new contracts were signed, and 13 units are ready for deployment, with FY 2025 guidance reaffirmed. Over AUD 140 million is available for future investment.
Fiscal Year 2024
-
Revenue grew 69% to AUD 45.4 million and EBITDA rose 156% to AUD 9 million, with 29 PhotonAssay units deployed and strong international expansion. FY25 guidance targets 45% revenue growth, supported by a robust contract pipeline and solid funding.
-
Revenue grew 58% year-on-year to AUD 45.4 million, with strong international expansion and record sample volumes. FY25 guidance targets AUD 60–70 million revenue and AUD 9–19 million EBITDA, assuming stable market conditions and continued deployment momentum.